Product Description
Mechanisms of Action: N/A
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Ireland | Israel | Italy | Japan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: AZIENDA OSPEDALIERA ARCISPEDALE S. MARIA NUOVA
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Belgium, Czech Republic, Italy
Active Clinical Trial Count: 4
Highest Development Phases
Phase 2: Abdominal Pain|Bronchopulmonary Dysplasia|Cardiac Arrest|Chronic Pain|Surgical Wound Infection
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| SRB2021260 | P2 |
Recruiting |
Cardiac Arrest |
2030-11-30 |
|
| EVENEW | P2 |
Recruiting |
Bronchopulmonary Dysplasia |
2028-06-30 |
|
| DUO2022_01 | P2 |
Unknown Status |
Surgical Wound Infection |
2025-12-31 |
|
| 2023-508224-35-01 | P2 |
Recruiting |
Chronic Pain|Abdominal Pain |
2025-03-31 |